Olympus Corporation, a prominent player operating within the Healthcare sector and specializing in Medical Devices, currently holds a substantial market capitalization of 1.48 Trillion JPY.

Our proprietary technical scoring system assigns the stock a Sell rating, reflecting a total score of -3. The asset's core trend is decidedly bearish, as the current price of JPY 1,348.00 trades significantly below the 200-day Simple Moving Average of JPY 1,837.98, triggering a -2 penalty. This downward trajectory is powerfully reinforced by trend strength indicators: an ADX of 48.08 combined with a dominant DMI- over the DMI+ adds another -1 to the score, highlighting a robust bear market. While the RSI sits at a neutral 32.15 (scoring 0) just shy of oversold territory, and the MACD histogram shows a mild bullish crossover (+1), the volume data remains discouraging. The On-Balance Volume (OBV) has fallen below its 5-day SMA, indicating ongoing distribution and netting a further -1. These predominantly negative technicals point to continued downward pressure.

From a fundamental and earnings perspective, the technical weakness is heavily corroborated. The company recently reported a highly concerning EPS of -5.39, which translated into a drastic negative surprise of -21,228.0%. While the stock features a P/E ratio of 15.61 and an anomalous recorded dividend yield of 225.0% (likely an extraordinary payout or data distortion), the severe earnings miss underscores significant operational headwinds. With the next quarterly earnings report scheduled for May 2026, the lack of immediate positive catalysts aligns perfectly with our technical Sell rating, suggesting investors should remain on the sidelines until structural improvements materialize.